
Barzolvolimab shows lasting improvement in angioedema for chronic spontaneous urticaria patients, with effects lasting 7 months post-treatment.
Celldex Therapeutics presented long-term Phase 2 results showing barzolvolimab provides rapid, significant, and durable relief from angioedema in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. Impre...



